Fichero a descargar de la publicaciÃ³n mostrada - Sociedad ...

More documents

Recommendations

Info

Octubre 2011 INFECCIONES RELACIONADAS CON CATÉTERES VASCULARES Pág. 48______________________________________________________________________________112. Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a metaanalysis.Ann Intern Med 1993; 119:304-11.113. Fowler VG Jr., Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureusbacteremia. Arch Intern Med 2003; 163:2066-72.114. Mitchell DH, Howden BP. Diagnosis and management of Staphylococcus aureus bacteraemia. Intern Med J2005; 35 Suppl 2:S17-S24.115. Sochowski RA, Chan KL. Implication of negative results on a monoplane transesophageal echocardiographicstudy in patients with suspected infective endocarditis. J Am Coll Cardiol 1993; 21:216-21.116. Rosen AB, Fowler VG Jr., Corey GR, et al. Cost-effectiveness of transesophageal echocardiography todetermine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. AnnIntern Med 1999; 130:810-20.117. Pigrau C, Rodríguez D, Planes AM, et al. Management of catheter-related Staphylococcus aureus bacteremia:when may sonographic study be unnecessary? Eur J Clin Microbiol Infect Dis 2003; 22:713-9.118. Raad I, Davis S, Khan A, Tarrand J, Elting L, Bodey GP. Impact of central venous catheter removal on therecurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol1992; 13:215-21.119. Zinkernagel AS, Zinkernagel MS, Elzi MV, et al. Significance of Staphylococcus lugdunensis bacteremia:report of 28 cases and review of the literature. Infection 2008; 36:314-21.120. Frank KL, Del Pozo JL, Patel R. From clinical microbiology to infection pathogenesis: how daring to bedifferent works for Staphylococcus lugdunensis. Clin Microbiol Rev 2008; 21:111-33.121. Raad II, Hanna HA, Boktour M, Jabbour N, Hachem RY, Darouiche RO. Catheter-related vancomycinresistantEnterococcus faecium bacteremia: clinical and molecular epidemiology. Infect Control Hosp Epidemiol2005; 26:658-61.122. McBride SJ, Upton A, Roberts SA. Clinical characteristics and outcomes of patients with vancomycinsusceptibleEnterococcus faecalis and Enterococcus faecium bacteraemia-a five-year retrospective review. Eur JClin Microbiol Infect Dis 2010; 29:107-14.123. Oteo J, Cuevas O, Navarro C, Aracil B, Campos J. Trends in antimicrobial resistance in 3469 enterococciisolated from blood (EARSS experience 2001-06, Spain): increasing ampicillin resistance in Enterococcusfaecium. J Antimicrob Chemother 2007; 59:1044-5.124. Martínez-Odriozola P, Muñoz-Sánchez J, Gutiérrez-Macías A, et al. [An analysis of 182 enterococcalbloodstream infections: epidemiology, microbiology, and outcome]. Enferm Infecc Microbiol Clin 2007;25:503-7.125. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment ofvancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007; 54:567-71.126. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. ClinMicrobiol Infect 2010; 16:555-62.127. Zimmer SM, Caliendo AM, Thigpen MC, Somani J. Failure of linezolid treatment for enterococcalendocarditis. Clin Infect Dis 2003; 37:e29-e30.128. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due tovancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357:1179.129. Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management.Medicine (Baltimore) 1988; 67:248-69.
Octubre 2011 INFECCIONES RELACIONADAS CON CATÉTERES VASCULARES Pág. 49______________________________________________________________________________130. Sandoe JA, Witherden IR, Au-Yeung HK, Kite P, Kerr KG, Wilcox MH. Enterococcal intravascular catheterrelatedbloodstream infection: management and outcome of 61 consecutive cases. J Antimicrob Chemother2002; 50:577-82.131. Mainardi JL, Gutmann L, Acar JF, Goldstein FW. Synergistic effect of amoxicillin and cefotaxime againstEnterococcus faecalis. Antimicrob Agents Chemother 1995; 39:1984-7.132. Gavalda J, Torres C, Tenorio C, et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimentalendocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob AgentsChemother 1999; 43:639-46.133. Cannon JP, Pachucki CT, Aneziokoro CO, Lentino JR. The Effectiveness and safety of oral linezolid asprimary or secondary treatment of bloodstream infections. Infectious Diseases in Clinical Practice 2006; 14:221-6.134. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in anin vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003;47:539-46.135. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faeciumresistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005; 49:5166-8.136. Snydman DR, McDermott LA, Jacobus NV. Evaluation of in vitro interaction of daptomycin with gentamicinor beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. JChemother 2005; 17:614-21.137. Warren RE. Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother2008; 62 Suppl 3:iii25-iii33.138. Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by anEnterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations andevidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007; 45:1343-6.139. Linden PK, Moellering RC Jr., Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faeciuminfections with quinupristin/dalfopristin. Clin Infect Dis 2001; 33:1816-23.140. Weinstein RA, Fridkin SK. The changing face of fungal infections in health care dettings. Clin Infect Dis2005; 41:1455-60.141. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-monthEuropean Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin MicrobiolInfect Dis 2004; 23:317-22.142. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplantrecipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181:309-16.143. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicentersurveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research andTreatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-9.144. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dosefluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequencesin nonneutropenic subjects. Clin Infect Dis 2003; 36:1221-8.145. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl JMed 2007; 356:2472-82.146. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35.
Page 1 and 2: AVANCES ENENFERMEDADES INFECCIOSASP
Page 3 and 4: Octubre 2011 INFECCIONES RELACIONAD
Page 47: Octubre 2011 INFECCIONES RELACIONAD

Fichero a descargar de la publicaciÃ³n mostrada - Sociedad ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?